ATE507242T1 - Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon - Google Patents

Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Info

Publication number
ATE507242T1
ATE507242T1 AT06755161T AT06755161T ATE507242T1 AT E507242 T1 ATE507242 T1 AT E507242T1 AT 06755161 T AT06755161 T AT 06755161T AT 06755161 T AT06755161 T AT 06755161T AT E507242 T1 ATE507242 T1 AT E507242T1
Authority
AT
Austria
Prior art keywords
binding molecules
host cell
applications
specific binding
human binding
Prior art date
Application number
AT06755161T
Other languages
English (en)
Inventor
Mark Throsby
Kruif Cornelis De
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE507242T1 publication Critical patent/ATE507242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06755161T 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon ATE507242T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP05/52160 2005-05-12
EPPCT/EP05/52648 2005-06-08
EPPCT/EP05/52946 2005-06-23
EPPCT/EP05/54002 2005-08-15
PCT/EP2006/062250 WO2006120230A2 (en) 2005-05-12 2006-05-11 Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Publications (1)

Publication Number Publication Date
ATE507242T1 true ATE507242T1 (de) 2011-05-15

Family

ID=37396920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755161T ATE507242T1 (de) 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Country Status (7)

Country Link
US (2) US8052974B2 (de)
EP (1) EP1879921B1 (de)
AT (1) ATE507242T1 (de)
AU (1) AU2006245734C1 (de)
CA (1) CA2608058C (de)
IL (1) IL187321A (de)
WO (1) WO2006120230A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314629B2 (de) 2002-07-18 2022-11-16 Merus N.V. Rekombinante Herstellung von Mischungen aus Aantikörpern
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005118644A2 (en) 2004-05-27 2005-12-15 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP2059532B1 (de) 2006-09-07 2012-12-26 Crucell Holland B.V. Humane bindungsmoleküle, die in der lage sind, das grippevirus h5n1 zu neutralisieren, und anwendungen davon
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2016138312A2 (en) * 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
JP6811723B2 (ja) * 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
CN107921127B (zh) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
BR112020003622A2 (pt) 2017-08-21 2020-09-01 Adagene Inc. cadeia pesada de anticorpo, anticorpo, bibliotecas, kit, método de preparo de uma biblioteca, método de produção de uma biblioteca de anticorpos, fago, método de geração de um anticorpo biespecífico e anticorpo biespecífico
WO2019036856A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. DYNAMIC BANKS OF LIGHT CHAIN OF HUMAN ANTIBODY

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529700A (en) 1982-08-20 1985-07-16 University Of Miami Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HU219503B (hu) 1994-07-08 2001-04-28 Baxter Aktiengesellschaft Javított vakcina TBE-vírusfertőzés elleni immunizálásra, valamint eljárás az előállítására
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
EP0947581A4 (de) 1996-08-08 2004-07-28 Mitsubishi Pharma Corp Kulturmedium und seine verwendung.
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
CA2282790C (en) 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
WO1999026653A1 (en) 1997-11-20 1999-06-03 United States Army Medical Research And Material Command Dna vaccines against tick-borne flaviviruses
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
EP1107961A4 (de) 1998-08-25 2002-01-30 Univ Yale Hemmung und behandlung des hepatitis b-virus und flavivirus durch helioxanthin und analoga davon
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU774045B2 (en) 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US6685948B1 (en) * 1998-09-02 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
WO2004042042A1 (en) 2002-11-08 2004-05-21 Crucell Holland B.V. Vaccines against west nile virus
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
CA2941182A1 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MXPA02012867A (es) * 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
US6946125B2 (en) * 2000-08-23 2005-09-20 The New York Hospital Medical Center Of Queens Methods of treating West Nile virus infection
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
AU2002365244B2 (en) 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
AU2003213022A1 (en) 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
US7351547B2 (en) 2002-10-31 2008-04-01 Health Research, Inc. Diagnostic test for West Nile virus
CA2491992A1 (en) 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CN100558895C (zh) 2003-07-18 2009-11-11 持田制药株式会社 抗血小板膜糖蛋白vi单克隆抗体
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ES2378767T3 (es) 2003-12-23 2012-04-17 Crucell Holland B.V. Molécula de unión humana contra CD1a
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
WO2005111623A1 (en) 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
WO2005118644A2 (en) 2004-05-27 2005-12-15 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
WO2005123774A2 (en) 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
US7527973B2 (en) 2004-06-21 2009-05-05 Washington University Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
CA2579142A1 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
WO2006040322A1 (en) 2004-10-12 2006-04-20 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
WO2007011392A2 (en) 2004-10-14 2007-01-25 Washington University Crystal structure of domain 111 of west nile virus envelope protein-fab fragment of neutralizing antibody complex
KR101255861B1 (ko) 2004-11-11 2013-04-17 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 조성물 및 그것의 용도
WO2006056006A1 (en) 2004-11-23 2006-06-01 The University Of Queensland Equine west nile virus immunotherapy
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (de) 2005-06-23 2008-03-05 Crucell Holland B.V. Optimierung von antikörpern gegen das west-nile-virus
CA2622603C (en) 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
EP2059532B1 (de) 2006-09-07 2012-12-26 Crucell Holland B.V. Humane bindungsmoleküle, die in der lage sind, das grippevirus h5n1 zu neutralisieren, und anwendungen davon

Also Published As

Publication number Publication date
CA2608058A1 (en) 2006-11-16
EP1879921B1 (de) 2011-04-27
WO2006120230A3 (en) 2007-06-21
US20120076794A1 (en) 2012-03-29
US20100303801A1 (en) 2010-12-02
CA2608058C (en) 2013-09-10
US8052974B2 (en) 2011-11-08
IL187321A (en) 2013-06-27
AU2006245734A1 (en) 2006-11-16
WO2006120230A2 (en) 2006-11-16
IL187321A0 (en) 2008-04-13
EP1879921A2 (de) 2008-01-23
US8911738B2 (en) 2014-12-16
AU2006245734C1 (en) 2012-05-24
AU2006245734B2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
ATE501171T1 (de) Bindungsmoleküle, die dazu fähig sind, das tollwutvirus zu neutralisieren, und anwendungen davon
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
CN110214154A (zh) 抗cd47抗体及其用途
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
NO20091321L (no) Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2007053189A3 (en) Compositions and methods for altering immune function
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EP2780460A4 (de) Modifizierte dna-bindende proteine und verwendungen davon
WO2014066744A3 (en) Anti-complement c1s antibodies and uses thereof
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
MX372950B (es) Anticuerpos.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
DE602006012786D1 (de) System und Methode zur Konzentrierung und Lyse von Zellen oder Viren
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
EP2593548A4 (de) Zusammensetzung aus dem menschlichen papillomavirus-antigen e7 und verwendungen davon
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties